Table 3.
NanoSight LM10 analysis of CFS EVs. Summary of EV number and size distribution, with or without the FTLA algorithm, quantified by NanoSight analysis
| Mean (nm) | Mode (nm) | SD (nm) | D10 (nm) | D50 (nm) | D90 (nm) | Total Concentration (Particles/mL) | Number of Completed Tracks | Number of Valid Tracks | ||
| Light scatter | FTLA size distribution | 196.4 ± 1.7 | 165.0 ± 3.1 | 104.2 ± 7.6 | 106.0 ± 1.2 | 172.0 ± 1.2 | 306.0 ± 8.0 | 7.43E11 ± 1.89E9 | 26006 | 8663 |
| size distribution | 194.1 ± 1.1 | 155.3 ± 2.4 | 117.7± 5.0 | 98.0 ± 1.2 | 168.7 ± 0.7 | 304.3 ± 2.3 | 7.43E11 ± 1.89E9 | 26006 | 8663 | |
| Fluorescent | FTLA size distribution | 227.7 ± 5.2 | 93.7 ± 7.5 | 228.8 ± 11.3 | 78.0 ± 2.0 | 150.7 ± 1.3 | 469.3 ± 17.4 | 3.47E11 ± 4.32E9 | 13839 | 4704 |
| size distribution | 214.3 ± 6.3 | 87.0 ± 7.1 | 235.2 ± 12.2 | 69.7 ± 1.2 | 142.7 ± 2.2 | 404.0 ± 17.8 | 3.47E11 ± 4.32E9 | 13839 | 4704 |
Mean and SD of three technical measurements for light scatter NTA and fluorescent NTA are shown. Concentrations adjusted for dilution factors. All values provided are batch average results from 3 technical replicates. D10 is the point in the size distribution where 10% of the sample is contained, D50 is the point where 50% of the sample is contained (median), and D90 is the point where 90% of the sample is contained. CFS: Cell-free saliva; EVs: extracellular vesicles; FTLA: finite track length adjustment; SD: standard deviation.